R
162.99
5.22 (3.31%)
| Previous Close | 157.77 |
| Open | 160.94 |
| Volume | 4,702,503 |
| Avg. Volume (3M) | 3,150,120 |
| Market Cap | 34,651,099,136 |
| Price / Sales | 9.04 |
| Price / Book | 23.09 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Revolution Medicines, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.80 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 105.87% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANDERS JACK | - | 156.58 | -2,722 | -426,211 |
| CISLINI JEFF | - | 156.58 | -2,157 | -337,743 |
| GOLDSMITH MARK A | - | 156.58 | -10,020 | -1,568,932 |
| HORN MARGARET A | - | 155.69 | -100,000 | -15,829,916 |
| KELSEY STEPHEN MICHAEL | - | 156.58 | -4,175 | -653,722 |
| MANCINI ANTHONY | - | 156.58 | -4,615 | -722,617 |
| Aggregate Net Quantity | -123,689 | |||
| Aggregate Net Value ($) | -19,539,140 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 156.25 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HORN MARGARET A | Officer | 17 Jun 2026 | Automatic sell (-) | 29,600 | 157.77 | 4,669,992 |
| HORN MARGARET A | Officer | 17 Jun 2026 | Option execute | 29,600 | - | - |
| KELSEY STEPHEN MICHAEL | Officer | 16 Jun 2026 | Automatic sell (-) | 4,175 | 156.58 | 653,722 |
| ANDERS JACK | Officer | 16 Jun 2026 | Automatic sell (-) | 2,722 | 156.58 | 426,211 |
| CISLINI JEFF | Officer | 16 Jun 2026 | Automatic sell (-) | 2,157 | 156.58 | 337,743 |
| GOLDSMITH MARK A | Officer | 16 Jun 2026 | Automatic sell (-) | 10,020 | 156.58 | 1,568,932 |
| MANCINI ANTHONY | Officer | 16 Jun 2026 | Sell (-) | 4,615 | 156.58 | 722,617 |
| HORN MARGARET A | Officer | 15 Jun 2026 | Automatic sell (-) | 60,400 | 160.06 | 9,667,624 |
| HORN MARGARET A | Officer | 15 Jun 2026 | Option execute | 60,400 | - | - |
| HORN MARGARET A | Officer | 11 Jun 2026 | Option execute | 10,000 | - | - |
| HORN MARGARET A | Officer | 11 Jun 2026 | Automatic sell (-) | 10,000 | 149.23 | 1,492,300 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 13 Apr 2026 | CNBC | Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |